Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Investigator left Northwestern University
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study seeks to examine if there is any relationship between spironolactone use prescribed for acne vulgaris and depression, anxiety, and/or sexual function.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Subjects on spironolactone for a diagnosis of acne vulgaris | Female subjects between 18 and 65 years of age currently taking spironolactone for a diagnosis of acne vulgaris |
| |
| Subjects on oral antibiotics for a diagnosis of acne vulgaris | Female subjects between 18 and 65 years of age currently taking oral antibiotics for a diagnosis of acne vulgaris |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Online survey | Other | Online survey completion through Northwestern's REDCap |
|
| Measure | Description | Time Frame |
|---|---|---|
| Percent correlation between spironolactone use for acne vulgaris and increased prevalence of depression. | Score for depression from subject reported Dermatology Life Quality Index (DLQI) survey | one week |
| Percent correlation between spironolactone use for acne vulgaris and increased prevalence of anxiety. | Score for depression from subject reported Generalized Anxiety Disorder (GAD-7) survey | two weeks |
| Percent correlation between spironolactone use for acne vulgaris and increased prevalence of sexual dysfunction. | Score for depression from subject reported Female Sexual Function Index (FSFI) survey. | four weeks |
Not provided
Not provided
Inclusion Criteria:
Female subjects between 18 and 65 years of age currently taking spironolactone for a diagnosis of acne vulgaris
OR
Female subjects between 18 and 65 years of age currently taking oral antibiotics for a diagnosis of acne vulgaris
AND Subjects able to complete an online survey in English
Exclusion Criteria:
Subjects less than 18 years of age or older than 65 years of age Subjects that have ever been diagnosed with any mood disorder by a clinician prior to starting spironolactone (history of mood disorder or current mood disorder) Subjects taking hormonal contraception (including but not limited to oral contraceptive pills) for a duration of less than 6 months Subjects that have ever been diagnosed with any type of sexual dysfunction prior to starting spironolactone Subjects not able to complete an online survey in English Subjects taking oral isotretinoin for a diagnosis of acne Subjects that are currently pregnant
Not provided
Biologically female subjects
Female patients who have acne vulgaris being treated with spironolactone or oral antibiotics.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bethanee Schlosser, MD | Northwestern University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Northwestern University | Chicago | Illinois | 60611 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000152 | Acne Vulgaris |
| ID | Term |
|---|---|
| D017486 | Acneiform Eruptions |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D012625 | Sebaceous Gland Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided